1. Home
  2. BANX vs NKTX Comparison

BANX vs NKTX Comparison

Compare BANX & NKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

BANX

ArrowMark Financial Corp.

HOLD

Current Price

$20.56

Market Cap

191.0M

Sector

Finance

ML Signal

HOLD

Logo Nkarta Inc.

NKTX

Nkarta Inc.

HOLD

Current Price

$2.63

Market Cap

198.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BANX
NKTX
Founded
N/A
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
191.0M
198.2M
IPO Year
2013
2020

Fundamental Metrics

Financial Performance
Metric
BANX
NKTX
Price
$20.56
$2.63
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$11.33
AVG Volume (30 Days)
35.7K
568.6K
Earning Date
01-01-0001
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
11.88
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$18.45
$1.70
52 Week High
$23.67
$3.72

Technical Indicators

Market Signals
Indicator
BANX
NKTX
Relative Strength Index (RSI) 55.52 56.61
Support Level $19.33 $2.59
Resistance Level $20.99 $2.81
Average True Range (ATR) 0.22 0.14
MACD -0.03 0.06
Stochastic Oscillator 48.15 80.37

Price Performance

Historical Comparison
BANX
NKTX

About BANX ArrowMark Financial Corp.

ArrowMark Financial Corp is a non-diversified, closed-end management investment company. The Fund's objective is to provide stockholders with current income, and to a lesser extent capital appreciation. The company's investments in various portfolios such as debt securities, Trust Preferred and Preferred Securities, preferred securities, exchange-traded funds, money market funds and others.

About NKTX Nkarta Inc.

Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK-cell expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.

Share on Social Networks: